Vanguard Capital Management’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
Other funds holding CLDX
KCM
BBA
Vanguard Capital Management's CLDX Position: Q3 2026 in Review
Vanguard Capital Management increased its Celldex Therapeutics (CLDX) stake by 0.32% in Q3 2026, buying an estimated $429K and bringing the position to 3,476,055 shares worth $113M. The position accounts for ﹤0.01% of the portfolio, ranked #1460.
Vanguard Capital Management first reported a position in CLDX in Q1 2026 and has held it in 3 quarters since. The position peaked at $129M in Q2 2026. 249 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.
- Vanguard Capital Management held 3,476,055 shares of Celldex Therapeutics worth $113M as of Q3 2026.
- Vanguard Capital Management bought 11,224 Celldex Therapeutics shares in Q3 2026, an estimated $429K.
- Celldex Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1460 holding.
- Vanguard Capital Management first reported a position in Celldex Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Celldex Therapeutics position peaked at $129M in Q2 2026.
- 249 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.